Suppr超能文献

C3H 10T1/2 C18细胞的5-氮杂-2'-脱氧胞苷抗性变体中的DNA甲基化

DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells.

作者信息

Flatau E, Gonzales F A, Michalowsky L A, Jones P A

出版信息

Mol Cell Biol. 1984 Oct;4(10):2098-102. doi: 10.1128/mcb.4.10.2098-2102.1984.

Abstract

A cell line (T17) was derived from C3H 10T1/2 C18 cells after 17 treatments with increasing concentrations of 5-aza-2'-deoxycytidine. The T17 cell line was very resistant to the cytotoxic effects of 5-aza-2'-deoxycytidine, and the 50% lethal dose for 5-aza-2'-deoxycytidine was ca. 3 microM, which was 30-fold greater than that of the parental C3H 10T1/2 C18 cells. Increased drug resistance was not due to a failure of the T17 cell line to incorporate 5-aza-2'-deoxycytidine into DNA. The cells were also slightly cross-resistant to 5-azacytidine. The percentage of cytosines modified to 5-methylcytosine in T17 cells was 0.7%, a 78% decrease from the level of 3.22% in C3H 10T1/2 C18 cells. The DNA cytosine methylation levels in several clones isolated from the treated lines were on the order of 0.7%, and clones with methylation levels lower than 0.45% were not obtained even after further drug treatments. These highly decreased methylation levels appeared to be unstable, and DNA modification increased as the cells divided in the absence of further drug treatment. The results suggest that it may not be possible to derive mouse cells with vanishingly low levels of 5-methylcytosine and that considerable de novo methylation can occur in cultured lines.

摘要

用浓度递增的5-氮杂-2'-脱氧胞苷对C3H 10T1/2 C18细胞进行17次处理后,获得了一个细胞系(T17)。T17细胞系对5-氮杂-2'-脱氧胞苷的细胞毒性作用具有很强的抗性,5-氮杂-2'-脱氧胞苷的50%致死剂量约为3 microM,这比亲代C3H 10T1/2 C18细胞高30倍。耐药性增加并非由于T17细胞系未能将5-氮杂-2'-脱氧胞苷掺入DNA。这些细胞对5-氮杂胞苷也有轻微的交叉抗性。T17细胞中被修饰为5-甲基胞嘧啶的胞嘧啶百分比为0.7%,比C3H 10T1/2 C18细胞中3.22%的水平降低了78%。从处理后的细胞系中分离出的几个克隆的DNA胞嘧啶甲基化水平约为0.7%,即使经过进一步的药物处理,也未获得甲基化水平低于0.45%的克隆。这些高度降低的甲基化水平似乎不稳定,并且在没有进一步药物处理的情况下,随着细胞分裂,DNA修饰会增加。结果表明,可能无法获得5-甲基胞嘧啶水平极低的小鼠细胞,并且在培养细胞系中可能会发生相当数量的从头甲基化。

相似文献

1
DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells.
Mol Cell Biol. 1984 Oct;4(10):2098-102. doi: 10.1128/mcb.4.10.2098-2102.1984.
3
Gene structure and transcription in mouse cells with extensively demethylated DNA.
Mol Cell Biol. 1989 Mar;9(3):885-92. doi: 10.1128/mcb.9.3.885-892.1989.
4
Oxygen concentration regulates 5-azacytidine-induced myogenesis in C3H/10T1/2 cultures.
Biochim Biophys Acta. 1990 Nov 12;1055(2):126-9. doi: 10.1016/0167-4889(90)90112-q.
8
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.
Leuk Res. 1984;8(2):181-5. doi: 10.1016/0145-2126(84)90141-3.
10
5-aza-2'-deoxycytidine induces alterations in murine spermatogenesis and pregnancy outcome.
J Androl. 2003 Nov-Dec;24(6):822-30. doi: 10.1002/j.1939-4640.2003.tb03133.x.

引用本文的文献

1
The Epitranscriptome in miRNAs: Crosstalk, Detection, and Function in Cancer.
Genes (Basel). 2022 Jul 21;13(7):1289. doi: 10.3390/genes13071289.
2
Lead exposure induces dysregulation of constitutive heterochromatin hallmarks in live cells.
Curr Res Toxicol. 2021 Dec 11;3:100061. doi: 10.1016/j.crtox.2021.12.001. eCollection 2022.
3
STAT3-mediated effects of methyltransferase inhibitor 5-aza-2'-deoxycytidine on preeclampsia.
Am J Transl Res. 2021 May 15;13(5):4103-4119. eCollection 2021.
4
The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark.
Wiley Interdiscip Rev RNA. 2019 Jan;10(1):e1510. doi: 10.1002/wrna.1510. Epub 2018 Oct 11.
5
DNA methylation and DNA methyltransferases.
Epigenetics Chromatin. 2017 May 8;10:23. doi: 10.1186/s13072-017-0130-8. eCollection 2017.
6
Inhibition of Methyltransferase 3B is a Potential Therapy for Hepatocellular Carcinoma.
Gastroenterology Res. 2008 Dec;1(1):33-39. doi: 10.4021/gr2008.10.1240. Epub 2008 Nov 20.
7
Demethylating Agents in the Treatment of Cancer.
Pharmaceuticals (Basel). 2010 Jul 2;3(7):2022-2044. doi: 10.3390/ph3072022.
8
Epigenetic Determinants of Cancer.
Cold Spring Harb Perspect Biol. 2016 Sep 1;8(9):a019505. doi: 10.1101/cshperspect.a019505.
9
γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?
Oncoimmunology. 2015 Apr 28;4(6):e1006088. doi: 10.1080/2162402X.2015.1006088. eCollection 2015 Jun.
10
Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells.
Nucleic Acids Res. 2014 Oct 29;42(19):e152. doi: 10.1093/nar/gku775. Epub 2014 Aug 26.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验